ABL1 and precursor B-cell acute lymphoblastic leukemia: Targeting of BCR-ABL, which is present in 15–25% of adult B-ALL patients, by tyrosine inhibitors such as Imatinib, Dasatinib and Ponatinib clearly improved the outcome for the respective patients [22].